Lumicell Inc.

Lumicell Inc. is a for-profit organization and manufacturer of goods registered to receive federal contract and grant awards since October 14, 2009. The company specializes in developing innovative medical imaging technologies, particularly focused on cancer detection and treatment. Lumicell's primary offerings to the federal government include advanced imaging systems and clinical trial support for cancer research and early detection methods. The company's expertise lies in creating cutting-edge fluorescence-based imaging technologies that aid in the early detection and treatment of various types of cancer.

In terms of federal contract awards, Lumicell has been involved in Small Business Innovation Research (SBIR) projects. A notable example is a recent contract (75N91024C00081) awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services. This contract, valued at $399,036.00, is for the clinical evaluation of a novel fluorescence endoscope and fluorescent probe specifically designed for the early detection of esophageal cancer. The contract is a definitive, firm-fixed-price agreement set aside for small businesses, with a completion date of September 15, 2025. This project showcases Lumicell's capabilities in developing advanced medical imaging technologies and conducting clinical trials for cancer detection applications.

Lumicell has also participated in federal grant activities as a sub-grantee in multiple research projects. The company's role in these grants primarily involves providing the LUM Imaging System, which includes an imaging agent (LUM015), imaging devices, disposable sterile barriers, and ancillary clinical trial supplies. Lumicell serves as the regulatory sponsor for these clinical studies, holding the necessary Investigational Device Exemption (IDE) from the FDA. The company provides comprehensive support for study management, including monitoring, data management and analysis, and oversight of study activities across multiple clinical sites. In one notable sub-grant award, Lumicell collaborated with The General Hospital Corporation, which served as the prime grantee. These grant activities highlight Lumicell's significant contributions to cancer research and clinical trials through its specialized imaging technology and regulatory expertise, further emphasizing the company's important role in advancing cancer detection and treatment methodologies.